FY21 operating earnings were in line with Credit Suisse estimates. The outlook for FY22 production is unchanged but mostly weighted to the second half because of mill maintenance in the September quarter and revised scheduling.
The stock remains the broker's top pick amongst intermediate gold stocks and an Outperform rating is maintained. Credit Suisse reduces the target to $3.60 from $4.00 after running new gold price forecasts and revising financing costs.
Target price is $3.60 Current Price is $2.48 Difference: $1.12
If RRL meets the Credit Suisse target it will return approximately 45% (excluding dividends, fees and charges).Current consensus price target is $3.38, suggesting upside of 36.4% (ex-dividends)
The company's fiscal year ends in June.
- Forums
- ASX - By Stock
- RRL
- Under valued
RRL
regis resources limited
Add to My Watchlist
2.23%
!
$4.39

Under valued, page-120
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$4.39 |
Change
-0.100(2.23%) |
Mkt cap ! $3.316B |
Open | High | Low | Value | Volume |
$4.47 | $4.53 | $4.37 | $16.81M | 3.793M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 51252 | $4.36 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$4.39 | 7201 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 4000 | 4.350 |
4 | 7325 | 4.300 |
1 | 1174 | 4.270 |
2 | 1435 | 4.250 |
1 | 2700 | 4.240 |
Price($) | Vol. | No. |
---|---|---|
4.420 | 5266 | 1 |
4.550 | 1000 | 1 |
4.570 | 222 | 1 |
4.580 | 6000 | 1 |
4.610 | 180 | 1 |
Last trade - 16.17pm 27/06/2025 (20 minute delay) ? |
Featured News
RRL (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online